Alpine Woods Capital Investors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.79M Buy
31,234
+2,190
+8% +$486K 1.63% 13
2025
Q4
$6.64M Sell
29,044
-5,985
-17% -$1.36M 1.58% 13
2025
Q3
$8.11M Sell
35,029
-374
-1% -$76.2K 1.89% 10
2025
Q2
$6.57M Buy
35,403
+642
+2% +$119K 1.56% 16
2025
Q1
$7.28M Sell
34,761
-8,732
-20% -$1.7M 1.83% 11
2024
Q4
$7.73M Buy
43,493
+10,050
+30% +$1.85M 1.46% 14
2024
Q3
$5.83M Buy
33,443
+4,282
+15% +$799K 1.02% 33
2024
Q2
$5M Sell
29,161
-155
-0.5% -$25.7K 0.77% 44
2024
Q1
$4.77M Sell
29,316
-23,107
-44% -$3.98M 0.95% 32
2023
Q4
$8.12M Sell
52,423
-275
-0.5% -$40.1K 1.21% 22
2023
Q3
$7.86M Sell
52,698
-1,948
-4% -$286K 1.27% 23
2023
Q2
$7.36M Sell
54,646
-15,358
-22% -$2.25M 1.15% 26
2023
Q1
$11.2M Sell
70,004
-4,374
-6% -$669K 1.69% 10
2022
Q4
$12M Buy
74,378
+12,159
+20% +$1.86M 1.75% 13
2022
Q3
$8.35M Buy
62,219
+3,426
+6% +$492K 1.14% 26
2022
Q2
$9.01M Sell
58,793
-190
-0.3% -$29K 1.13% 27
2022
Q1
$9.56M Sell
58,983
-9,470
-14% -$1.38M 1.01% 29
2021
Q4
$9.27M Sell
68,453
-1,231
-2% -$145K 0.92% 31
2021
Q3
$7.52M Buy
69,684
+3,494
+5% +$399K 0.8% 41
2021
Q2
$7.46M Sell
66,190
-7
-0% -$788 0.77% 43
2021
Q1
$7.16M Buy
66,197
+4,906
+8% +$525K 0.79% 39
2020
Q4
$6.57M Buy
61,291
+24,462
+66% +$2.35M 0.8% 38
2020
Q3
$3.23M Buy
36,829
+590
+2% +$55.5K 0.49% 71
2020
Q2
$3.56M Sell
36,239
-2,030
-5% -$179K 0.68% 43
2020
Q1
$2.92M Hold
38,269
0.65% 37
2019
Q4
$3.39M Hold
38,269
0.64% 40
2019
Q3
$2.9M Sell
38,269
-704
-2% -$48.3K 0.53% 39
2019
Q2
$2.83M Sell
38,973
-500
-1% -$39.3K 0.59% 43
2019
Q1
$3.18M Sell
39,473
-1,580
-4% -$129K 0.69% 31
2018
Q4
$3.79M Buy
41,053
+6,270
+18% +$551K 0.91% 21
2018
Q3
$3.29M Hold
34,783
0.68% 37
2018
Q2
$3.22M Hold
34,783
0.7% 33
2018
Q1
$3.29M Hold
34,783
0.17% 142
2017
Q4
$3.36M Buy
34,783
+3,000
+9% +$283K 0.17% 148
2017
Q3
$2.82M Hold
31,783
0.14% 155
2017
Q2
$2.31M Hold
31,783
0.12% 162
2017
Q1
$2.07M Sell
31,783
-500
-2% -$31.4K 0.11% 174
2016
Q4
$2.02M Sell
32,283
-150
-0.5% -$9.16K 0.11% 175
2016
Q3
$2.04M Hold
32,433
0.11% 178
2016
Q2
$2.01M Sell
32,433
-200
-0.6% -$12.2K 0.12% 168
2016
Q1
$1.86M Hold
32,633
0.11% 171
2015
Q4
$1.93M Sell
32,633
-1,800
-5% -$104K 0.1% 182
2015
Q3
$1.87M Buy
34,433
+300
+0.9% +$19.5K 0.1% 194
2015
Q2
$2.29M Sell
34,133
-400
-1% -$26.1K 0.12% 179
2015
Q1
$2.02M Sell
34,533
-14,900
-30% -$900K 0.1% 188
2014
Q4
$3.23M Buy
49,433
+150
+0.3% +$9.46K 0.17% 137
2014
Q3
$2.85M Hold
49,283
0.15% 145
2014
Q2
$2.78K Buy
49,283
+3,150
+7% +$165K 0.07% 133
2014
Q1
$2.37M Sell
46,133
-250
-0.5% -$12.6K 0.13% 139
2013
Q4
$2.45M Buy
46,383
+25,200
+119% +$1.24M 0.14% 138
2013
Q3
$948K Buy
21,183
+150
+0.7% +$6.65K 0.06% 204
2013
Q2
$869K Buy
+21,033
New +$920K 0.06% 198

Other funds holding ABBV

Alpine Woods Capital Investors's ABBV Position: Q1 2026 in Review

Alpine Woods Capital Investors increased its AbbVie (ABBV) stake by 7.5% in Q1 2026, buying an estimated $486K and bringing the position to 31,234 shares worth $6.79M. The position accounts for 1.63% of the portfolio, ranked #13.

Alpine Woods Capital Investors first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $12M in Q4 2022. 4,081 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Alpine Woods Capital Investors held 31,234 shares of AbbVie worth $6.79M as of Q1 2026.
  • Alpine Woods Capital Investors bought 2,190 AbbVie shares in Q1 2026, an estimated $486K.
  • AbbVie made up 1.63% of Alpine Woods Capital Investors's portfolio in Q1 2026, its #13 holding.
  • Alpine Woods Capital Investors first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Alpine Woods Capital Investors's AbbVie position peaked at $12M in Q4 2022.
  • 4,081 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Alpine Woods Capital Investors's 13F filing for Q1 2026, filed 27 May 2026.